NCT06935552View on ClinicalTrials.gov

Ketamine and Lidocaine Infusion in Refractory Chronic Migraine

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions
Refractory Chronic Migraine
Interventions
DRUG

Ketamine infusion

group A will receive ketamine intravenous infusion

DRUG

Lidocaine Intravenous Infusion

group B will receive lidocaine intravenous infusion

DRUG

Dextrose 5% in water

group C will only receive Dextrose 5% in water

All Listed Sponsors
lead

Assiut University

OTHER

NCT06935552 - Ketamine and Lidocaine Infusion in Refractory Chronic Migraine | Biotech Hunter | Biotech Hunter